New Antibody-Drug Conjugate Improves Advanced Endometrial Cancer Survival

An international Phase III clinical trial, TroFuse-005/ENGOT-en23/GOG-3095, has demonstrated that sacituzumab tirumotecan (sac-TMT), a new antibody-drug conjugate, significantly improves disease control and survival in patients with advanced or recurrent endometrial cancer. Presented at ESMO 2026 and published in The Lancet, these findings offer a crucial new therapeutic option for patients whose disease has progressed after prior chemotherapy and immunotherapy, addressing a significant unmet medical need.